PA8472101A1 - Combinaciones terapeuticas para la fragilidad musculo esquelectica - Google Patents

Combinaciones terapeuticas para la fragilidad musculo esquelectica

Info

Publication number
PA8472101A1
PA8472101A1 PA19998472101A PA8472101A PA8472101A1 PA 8472101 A1 PA8472101 A1 PA 8472101A1 PA 19998472101 A PA19998472101 A PA 19998472101A PA 8472101 A PA8472101 A PA 8472101A PA 8472101 A1 PA8472101 A1 PA 8472101A1
Authority
PA
Panama
Prior art keywords
compositions
fragility
pharmaceutically acceptable
acceptable salt
skeletal muscle
Prior art date
Application number
PA19998472101A
Other languages
English (en)
Spanish (es)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8472101A1 publication Critical patent/PA8472101A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PA19998472101A 1998-06-16 1999-05-07 Combinaciones terapeuticas para la fragilidad musculo esquelectica PA8472101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
PA8472101A1 true PA8472101A1 (es) 2000-09-29

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998472101A PA8472101A1 (es) 1998-06-16 1999-05-07 Combinaciones terapeuticas para la fragilidad musculo esquelectica

Country Status (29)

Country Link
EP (1) EP1085867A1 (sk)
JP (1) JP2002518328A (sk)
KR (1) KR20010052817A (sk)
CN (1) CN1305378A (sk)
AP (1) AP9901581A0 (sk)
AR (1) AR018868A1 (sk)
AU (1) AU3342099A (sk)
BG (1) BG105128A (sk)
BR (1) BR9911357A (sk)
CA (1) CA2335112A1 (sk)
CO (1) CO5070586A1 (sk)
EA (1) EA200001189A1 (sk)
GT (1) GT199900083A (sk)
HR (1) HRP20000857A2 (sk)
HU (1) HUP0102395A2 (sk)
ID (1) ID26726A (sk)
IL (1) IL139587A0 (sk)
IS (1) IS5727A (sk)
MA (1) MA26648A1 (sk)
NO (1) NO20006381L (sk)
OA (1) OA11569A (sk)
PA (1) PA8472101A1 (sk)
PE (1) PE20000633A1 (sk)
PL (1) PL345064A1 (sk)
SK (1) SK18902000A3 (sk)
TN (1) TNSN99118A1 (sk)
UY (1) UY25557A1 (sk)
WO (1) WO1999065488A1 (sk)
ZA (1) ZA993973B (sk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (pt) * 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
BR0214801A (pt) * 2001-11-29 2005-01-11 Gtx Inc Prevenção e tratamento de osteoporose induzida pela privação de andrógeno
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
ID26726A (id) 2001-02-01
KR20010052817A (ko) 2001-06-25
MA26648A1 (fr) 2004-12-20
WO1999065488A1 (en) 1999-12-23
BR9911357A (pt) 2001-03-13
EP1085867A1 (en) 2001-03-28
PE20000633A1 (es) 2000-07-26
AP9901581A0 (en) 1999-06-30
NO20006381D0 (no) 2000-12-14
BG105128A (en) 2001-11-30
TNSN99118A1 (fr) 2005-11-10
HRP20000857A2 (en) 2001-10-31
IS5727A (is) 2000-11-24
CN1305378A (zh) 2001-07-25
CO5070586A1 (es) 2001-08-28
IL139587A0 (en) 2002-02-10
NO20006381L (no) 2000-12-14
HUP0102395A2 (hu) 2001-11-28
ZA993973B (en) 2000-12-15
SK18902000A3 (sk) 2001-12-03
AR018868A1 (es) 2001-12-12
CA2335112A1 (en) 1999-12-23
AU3342099A (en) 2000-01-05
PL345064A1 (en) 2001-11-19
EA200001189A1 (ru) 2001-06-25
OA11569A (en) 2004-07-01
GT199900083A (es) 2000-12-05
JP2002518328A (ja) 2002-06-25
UY25557A1 (es) 2001-01-31

Similar Documents

Publication Publication Date Title
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
PT1222195E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
GT199800083A (es) Agonistas de prostaglandinas.
PA8635901A1 (es) Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
GT199800106A (es) Azetidinas.
PA8472101A1 (es) Combinaciones terapeuticas para la fragilidad musculo esquelectica
PA8475901A1 (es) Terapia de combinacion para la fragilidad musculoesqueletica
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
HUP0204258A3 (en) Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
MX9204010A (es) Composicion farmaceutica que contiene 3(3-piridil)-1h,3-pirrol[1,2- c]tiazol-7-carboxamida y procedimiento para su preparacion.
BR9904146A (pt) Combinações terapêuticas que incluem um modulador seletivo de receptores de estrogênio e protaglandina e2.
TH48282A (th) การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน
DE60301277D1 (de) Pharmazeutische zubereitung enthaltend valaciclovir
UY26651A1 (es) Terapia combinada para la osteoporosis
ECSP972347A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ITMI20010971A0 (it) Formulazioni farmaceutiche e/o dietetiche contenenti colostro e uso del colostro per il trattamento dell'acne